Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 4Osteosarcoma 2Neoplasms 2Chondrosarcoma 2Uterine Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1Adenoviridae Infections 1

Interventions

Vincristine 25Cyclophosphamide 25Irinotecan 21Temozolomide 18Doxorubicin 16Radiotherapy 15Filgrastim 15Ifosfamide 14Dactinomycin 14Etoposide 11Vinorelbine 9Melphalan 9Magnetic Resonance Spectroscopy 9Granulocyte Colony-Stimulating Factor 9Radiation 8pegfilgrastim 7X-Rays 7Specimen Handling 7Sirolimus 7Topotecan 6Phantoms, Imaging 6Peripheral Blood Stem Cell Transplantation 6Gemcitabine 6cixutumumab 5Busulfan 5Biopsy 5temsirolimus 4irinotecan sucrosofate 4fludarabine 4etoposide phosphate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma × Immune Checkpoint Inhibitors × Sarcoma × Clear all
NCT04995003 2026-01-22

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Baylor College of Medicine

Phase 1 Recruiting
25 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡